Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
North Carolina Republicans seek hundreds of millions of dollars more for school vouchersBernie Williams to raise awareness of lung disease at May 3 event in Puerto RicoUnited Methodists repeal longstanding ban on LGBTQ clergyWhat are the most memorable Kentucky Derby races?Fury road! Anya TaylorUnited Methodists repeal longstanding ban on LGBTQ clergyJessica Simpson, 43, is a pretty pinup in a lowSouth Carolina Senate takes up ban on genderWe're proof cancer is NOT an old person's disease: Two women struck down with the 'CFACEOFF: Rookie goaltender Joseph Woll stands tall, gives Maple Leafs life against Bruins
2.3554s , 6605.3671875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Planet Pulse news portal